Advertisement

Trials of Experimental Alzheimer's Drug Disappoint — Physician’s First Watch

Medical News |
August 8, 2012

Trials of Experimental Alzheimer's Drug Disappoint

Development of the intravenous formulation of an Alzheimer disease drug, bapineuzumab, has been halted after two clinical trials found that patients with mild-to-moderate disease failed to show cognitive or functional improvement, according to a Reuters report.

The drug is a monoclonal antibody that attacks beta-amyloid. In the phase III trial released this week, bapineuzumab did not improve performance in patients without a variation of the gene ApoE4. In July, Pfizer said that the drug also failed in patients with the ApoE4 variation.

Phase II trials of a subcutaneous formulation will continue.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement